Skip to main content
. 2022 Feb 23;147(3):281–287. doi: 10.1159/000523717

Fig. 2.

Fig. 2

a Presence of preclinical HF at the end of follow-up. b aOR for the risk of preclinical HF at the end of follow-up. MS, metabolic syndrome; HTN, hypertension; eWC, elevated waist circumference; aOR, adjusted odds ratio; LCL, lower confidence limit; UCL, upper confidence limit.